Российский кардиологический журнал, 2020 Aim. To assess azilsartan medoxomil (AZM) in achieving the target blood pressure (BP) (<140/90 mm Hg), its angioprotective action in patients with hypertension (HTN), as well as contribution in reducing levels of adipokines and inflammation markers in
S. V. Nedogoda +6 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2023 Aim. To study the effect of azilsartan medoxomil (AZL-M) on the 24-hour blood pressure (BP) profile in patients with hypertension (HTN), type 2 diabetes (T2D) and stable coronary artery disease (CAD).Material and methods.
A. M. Kochergina, O. L. Barbarash
doaj +1 more source
Synthesis and characterization of related substances of Azilsartan Kamedoxomil
Current Issues in Pharmacy and Medical Sciences, 2017 Azilsartan Kamedoxomil is an AT1-subtype angiotensin II receptor blocker (ARB). During the laboratory synthesis of Azilsartan Kamedoxomil, four related substances of Azilsartan Kamedoxomil were observed and identified.
Maddi N. V. D. Harikiran +4 more
doaj +1 more source
A novel method to determine new potent angiotensin inhibitor, azilsartan, in human plasma via micelle-enhanced spectrofluorimetry using cremophor RH 40 [PDF]
, 2016 Purpose: To develop a micelle-enhanced spectrofluorimetric method for the assay of azilsartan (AZL) in bulk form and spiked human plasma without the need for derivatization procedure.Method: The proposed method was based on studying the fluorescence ...
Abdelhameed, Ali S. +3 more
core +2 more sources
A prospective comparative efficacy of azilsartan and telmisartan in hypertensive patients [PDF]
, 2020 Background: Hypertension (HT) is defined as either a sustained systolic blood pressure of greater than 140 mmHg or a sustained diastolic blood pressure of greater than 90 mmHg, according to joint national committee (JNC VIII) on hypertension.Methods: A ...
Pandian J., Johan, R., Velvizhy
core +2 more sources
Российский кардиологический журнал, 2019 Aim. To assess the possibility of azilsartan medoxomil to achieve target blood pressure (BP) (less than 130/80 mm Hg), to study angioprotective features and reduction of adipokines levels and inflammatory markers in patients with hypertension and ...
S. V. Nedogoda +5 more
doaj +1 more source
Azilsartan: the novel ARB with unique mechanism of action [PDF]
, 2017 Hypertension is attributed to be one of the major risk factors in the pathophysiology of ischemic heart disease, stroke, heart failure and renal dysfunction.
Chinchansur, Sunny R. +4 more
core +2 more sources
Comparative study of efficacy and adverse effects profile of azilsartan, olmesartan and candesartan in the control of essential hypertension [PDF]
, 2017 Background: Hypertension has been identified as the leading risk factor for mortality worldwide. It may lead to damage of heart, kidney, brain, vasculature and the other organs results in premature morbidity and death.
Sinha, Hemant Kr., Zaman, Zaki A.
core +2 more sources
Preparation and evaluation of lipid matrix microencapsulation for drug delivery of azilsartan kamedoxomil [PDF]
, 2022 The aim of the work is to consolidate azilsartan-kamedoxomil (AZM) into lipid matrix controlled-release microparticles to enhance its permeability because AZM belongs to Biopharmaceutical classification (BCS) IV which characterized by poor permeability ...
Firas Aziz Rahi +2 more
core +3 more sources
QUALITY CONTROL ASSAY OF TWO ANTIHYPERTENSIVE REPRESENTATIVES USING RP-HPLC BASED METHODOLOGY: STRESS ASSESSMENT ON ANTIHYPERTENSIVE REPRESENTATIVES [PDF]
, 2022 Objective: A quick simultaneous separation and quality control assay of two antihypertensive representatives, Azilsartan (AZIL) and Cilnidipine (CLIN) in bulk and tablet formulation was developed and validated using a Reverse phase (RP) HPLC method ...
MANDAL, BADAL KUMAR +1 more
core +1 more source